Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#41 / 200 Total
PRCT - Procept BioRobotics Corp - Stock Price Chart
TickerPRCT [NASD, RUT]
CompanyProcept BioRobotics Corp
CountryUSA
IndustryMedical Devices
Market Cap3.12BEPS (ttm)-2.25
P/E-EPS this Y12.97%
Forward P/E-EPS next Y22.75%
PEG-EPS past 5Y-23.27%
P/S22.88EPS next 5Y10.80%
P/B10.96EPS Q/Q13.60%
Dividend-Sales Q/Q83.29%
Insider Own4.70%Inst Own88.48%
Insider Trans-13.00%Inst Trans-6.33%
Short Float10.94%EarningsMay 01/a
Analyst Recom1.22Target Price58.57
Avg Volume501.61K52W Range24.83 - 54.79
PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. It manufactures and sells the AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating BPH. The firm's proprietary AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The company was founded by Nikolai Aljuri and Rodney C. Perkins in 2007 and is headquartered in San Jose, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zadno RezaPresident, CEOMar 18 '24Sale48.835,391263,243241,319Mar 20 04:46 PM
Waters KevinEVP, CFOMar 18 '24Sale48.831,02450,002102,149Mar 20 04:48 PM
Nouri AlalehEVP, CLO, CORP. SEC.Mar 18 '24Sale48.8344121,53462,472Mar 20 04:52 PM
Shiblaq HishamEVP, Chief Comm. OfficerMar 18 '24Sale48.8324411,91555,860Mar 20 04:41 PM
Waters KevinEVP, CFOMar 15 '24Option Exercise4.5353,757243,692103,173Mar 18 06:05 PM
XNCR - Xencor Inc - Stock Price Chart
TickerXNCR [NASD, RUT]
CompanyXencor Inc
CountryUSA
IndustryBiotechnology
Market Cap1.48BEPS (ttm)-2.10
P/E-EPS this Y-66.34%
Forward P/E-EPS next Y15.08%
PEG-EPS past 5Y-9.81%
P/S8.76EPS next 5Y-
P/B2.18EPS Q/Q-56.17%
Dividend-Sales Q/Q106.80%
Insider Own2.72%Inst Own101.70%
Insider Trans-8.02%Inst Trans-2.45%
Short Float10.37%EarningsFeb 27/a
Analyst Recom1.46Target Price35.83
Avg Volume696.01K52W Range16.49 - 28.96
Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dahiyat Bassil IPRESIDENT & CEOMar 11 '24Sale23.502,74164,418351,894Mar 12 04:03 PM
Desjarlais John RSR. VICE PRESIDENT & CSOMar 11 '24Sale23.501,28030,082186,433Mar 12 04:05 PM
Eckert CeliaSVP, GENERAL COUNSELMar 11 '24Sale23.5085019,97745,465Mar 12 04:06 PM
Kuch John JSR. VICE PRESIDENT & CFOMar 11 '24Sale23.5084919,953121,070Mar 12 04:08 PM
GUSTAFSON KURT ADirectorMar 06 '24Option Exercise10.7315,000160,95020,007Mar 07 04:10 PM
GVP - GSE Systems, Inc. - Stock Price Chart
TickerGVP [NASD]
CompanyGSE Systems, Inc.
CountryUSA
IndustrySoftware - Application
Market Cap8.72MEPS (ttm)-3.54
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-81.20%
P/S0.19EPS next 5Y-
P/B1.53EPS Q/Q-19.86%
Dividend-Sales Q/Q-5.56%
Insider Own22.88%Inst Own10.89%
Insider Trans0.00%Inst Trans6.01%
Short Float1.97%EarningsApr 01/a
Analyst Recom1.00Target Price13.00
Avg Volume49.64K52W Range1.21 - 6.80
GSE Systems, Inc. engages in the provision of engineering services, staffing, and simulation software. It operates through the Performance Improvement Solutions and Nuclear Industry Training and Consulting segments. The Performance Improvement Solutions segment includes power plant high-fidelity simulation solutions, technical engineering services for ASME programs, power plant thermal performance optimization, and interactive computer-based tutorials/simulation. The Nuclear Industry Training and Consulting segment focuses on nuclear operations instructors, procedure writers, technical engineers, and other consultants to the nuclear power industry. The company was founded on March 30, 1994 and is headquartered in Columbia, MD.
TRN - Trinity Industries, Inc. - Stock Price Chart
TickerTRN [NYSE, RUT]
CompanyTrinity Industries, Inc.
CountryUSA
IndustryRailroads
Market Cap2.42BEPS (ttm)1.27
P/E23.27EPS this Y5.07%
Forward P/E14.50EPS next Y40.52%
PEG2.33EPS past 5Y3.52%
P/S0.81EPS next 5Y10.00%
P/B2.33EPS Q/Q99.71%
Dividend3.65%Sales Q/Q34.96%
Insider Own1.35%Inst Own83.25%
Insider Trans-3.51%Inst Trans-0.31%
Short Float2.13%EarningsMay 01/b
Analyst Recom2.00Target Price32.67
Avg Volume525.93K52W Range20.04 - 28.86
Trinity Industries, Inc. engages in the provision of rail transportation products and services in North America. It operates through the following segments: Railcar Leasing and Management Services Group, Rail Products Group, and Corporate and Other. The Railcar Leasing and Management Services Group segment owns and operates a fleet of railcars and provides third-party fleet leasing, management, and administrative services, as well as other railcar logistics products and services. The Rail Products Group segment manufactures and sells railcars and related parts and components and provides railcar maintenance and modification services. The company was founded in 1933 and is headquartered in Dallas, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Marchetto Eric REVP & CFOMar 27 '24Sale28.009,781273,868233,704Mar 29 04:02 PM
Poet KevinEVP Operations & Support SvcsMar 06 '24Sale25.456,000152,70030,718Mar 08 04:16 PM
Marchetto Eric REVP & CFODec 13 '23Sale27.0011,863320,301250,402Dec 14 05:05 PM
Mitchell Gregory BEVP & Chief Commercial OfficerNov 08 '23Sale23.1712,536290,459127,714Nov 13 05:05 PM
Marchetto Eric REVP & CFOSep 28 '23Sale25.0011,765294,125262,265Sep 29 04:54 PM
STGW - Stagwell Inc - Stock Price Chart
TickerSTGW [NASD, RUT]
CompanyStagwell Inc
CountryUSA
IndustryAdvertising Agencies
Market Cap787.97MEPS (ttm)-0.03
P/E-EPS this Y38.89%
Forward P/E7.78EPS next Y9.47%
PEG-EPS past 5Y-
P/S0.31EPS next 5Y6.00%
P/B2.24EPS Q/Q120.87%
Dividend-Sales Q/Q-9.40%
Insider Own4.38%Inst Own82.21%
Insider Trans0.49%Inst Trans0.95%
Short Float4.33%EarningsMay 01/b
Analyst Recom1.57Target Price7.43
Avg Volume534.05K52W Range3.83 - 8.59
Stagwell, Inc. operates as media and public relations agency. It delivers brands that connect culture-moving creativity with technology to harmonize the art and science of marketing. It operates through the following segments: Integrated Agencies Network, Media Network, Communications Network, All Other, and Corporate. The Integrated Agencies Network segment engages in the organization of go-to-market and collaboration incentive purposes to facilitate integrated and flexible offerings for clients. The Media Network segment consists of a specialist network branded as Stagwell Media Network. The Communications Network segment focuses on a specialist network that provides advocacy, strategic corporate communications, investor relations, public relations, online fundraising and other services to both corporations and political and advocacy organizations and consists of Allison & Partners SKDK (including Sloane & Company), and Targeted Victory Agencies. The All Other segment consists of Stagwell Marketing Cloud products such as PRophet. The Corporate segment includes corporate office expenses. The company was founded in 2015 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Penn Mark JefferyChief Executive OfficerFeb 29 '24Buy5.2810,00052,7592,490,469Feb 29 07:19 PM
Penn Mark JefferyChief Executive OfficerFeb 28 '24Buy5.2010,00052,0002,480,469Feb 28 07:48 PM
Oosterman WadeDirectorFeb 28 '24Buy5.045,00025,200128,204Feb 28 07:48 PM
Penn Mark JefferyChief Executive OfficerJan 19 '24Option Exercise2.19500,0001,095,0003,040,493Jan 23 06:00 PM
Penn Mark JefferyChief Executive OfficerDec 06 '23Option Exercise2.19500,0001,095,0003,040,493Dec 08 08:30 PM
TROO - TROOPS Inc - Stock Price Chart
TickerTROO [NASD]
CompanyTROOPS Inc
CountryHong Kong
IndustrySoftware - Application
Market Cap130.05MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y67.84%
P/S-EPS next 5Y-
P/B-EPS Q/Q111.53%
Dividend-Sales Q/Q-18.71%
Insider Own53.41%Inst Own0.12%
Insider Trans0.00%Inst Trans-39.02%
Short Float0.49%Earnings-
Analyst Recom-Target Price-
Avg Volume188.54K52W Range1.04 - 4.99
TROOPS, Inc. is a holding company, which engages in environmental protection, energy saving technologies, equipment development and applications, money lending business in Hong Kong providing mortgage loans to high quality target borrowers and property investment to generate additional rental income. It operates through the following segments: Liquid Crystal Display (LCD)/Light Emitting Diode (LED) Products, Green Energy Products and Services, VR Products and Services, Money Lending Services, Property Lease and Management, Financial Technology Solutions and Services and, Corporate. The company was founded on July 18, 2007 and is headquartered in Hong Kong.
NRBO - NeuroBo Pharmaceuticals Inc - Stock Price Chart
TickerNRBO [NASD]
CompanyNeuroBo Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap18.07MEPS (ttm)-2.46
P/E-EPS this Y-42.28%
Forward P/E-EPS next Y36.57%
PEG-EPS past 5Y69.13%
P/S-EPS next 5Y-
P/B1.08EPS Q/Q28.87%
Dividend-Sales Q/Q-
Insider Own59.79%Inst Own2.09%
Insider Trans0.00%Inst Trans-29.31%
Short Float2.63%EarningsMar 28/b
Analyst Recom1.00Target Price36.50
Avg Volume1.33M52W Range2.89 - 6.75
Apr-30-24 08:01AM NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June (PR Newswire)
Apr-17-24 08:05AM NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity (PR Newswire)
Apr-01-24 08:01AM NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH (PR Newswire)
Mar-28-24 08:01AM NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update (PR Newswire) -5.76%
Mar-13-24 08:01AM NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH (PR Newswire) -8.21%
Mar-04-24 08:01AM NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer (PR Newswire)
Feb-29-24 08:01AM NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity (PR Newswire) +13.09%
Feb-12-24 08:01AM NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference (PR Newswire) +9.65%
Feb-01-24 08:01AM NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity (PR Newswire) +67.28%
Jan-18-24 08:01AM NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH (PR Newswire)
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.
NXTC - Nextcure Inc - Stock Price Chart
TickerNXTC [NASD]
CompanyNextcure Inc
CountryUSA
IndustryBiotechnology
Market Cap38.32MEPS (ttm)-2.25
P/E-EPS this Y25.78%
Forward P/E-EPS next Y-0.90%
PEG-EPS past 5Y-17.56%
P/S-EPS next 5Y-
P/B0.33EPS Q/Q16.78%
Dividend-Sales Q/Q-
Insider Own24.39%Inst Own37.74%
Insider Trans0.00%Inst Trans4.92%
Short Float0.54%EarningsMar 21/b
Analyst Recom1.40Target Price5.00
Avg Volume293.33K52W Range0.98 - 2.57
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.
PEPG - PepGen Inc - Stock Price Chart
TickerPEPG [NASD, RUT]
CompanyPepGen Inc
CountryUSA
IndustryBiotechnology
Market Cap450.22MEPS (ttm)-3.30
P/E-EPS this Y12.79%
Forward P/E-EPS next Y4.72%
PEG-EPS past 5Y-172.30%
P/S-EPS next 5Y-
P/B3.05EPS Q/Q-29.94%
Dividend-Sales Q/Q-
Insider Own16.17%Inst Own60.39%
Insider Trans95.56%Inst Trans-0.43%
Short Float1.25%EarningsMar 06/a
Analyst Recom1.00Target Price21.60
Avg Volume115.47K52W Range3.72 - 17.51
PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RA CAPITAL MANAGEMENT, L.P.DirectorFeb 09 '24Buy10.642,557,59327,212,7909,179,273Feb 13 04:33 PM
McArthur James GPresident and CEONov 30 '23Buy4.171,6947,0561,694Dec 05 07:34 AM
McArthur James GPresident and CEOJun 08 '23Option Exercise2.712,3816,4532,381Jun 09 07:06 PM
McArthur James GPresident and CEOJun 08 '23Sale16.042,38138,1880Jun 09 07:06 PM
McArthur James GPresident and CEOJun 07 '23Option Exercise2.718,41922,8158,419Jun 08 05:23 PM
CADL - Candel Therapeutics Inc - Stock Price Chart
TickerCADL [NASD]
CompanyCandel Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap234.21MEPS (ttm)-1.31
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-46.75%
P/S-EPS next 5Y-
P/B18.29EPS Q/Q-117.62%
Dividend-Sales Q/Q-100.00%
Insider Own46.65%Inst Own5.81%
Insider Trans0.00%Inst Trans-0.72%
Short Float12.96%EarningsMar 28/b
Analyst Recom1.00Target Price11.00
Avg Volume5.33M52W Range0.66 - 11.40
Candel Therapeutics, Inc. is a late clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.
1234567891020